Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes
Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates
Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149
The authorisation enables emergency use of Actemra/RoActemra for the treatment of COVID-19 in hospitalised adult…
Availability of the Q2 2021 Memorandum for modelling purposes Paris,…
Press Release Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution),…
Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients…
Timeline Guidance for Both Programs Confirmed Leuven, BE, Boston, MA, US – June 25, 2021…
Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced…
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES….
Ultrasonic Technology to Heal Diabetic Foot Ulcers DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) —…
Lille, France; Cambridge, MA; June 24, 2021 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage…
— Christopher J. DeRespino appointed acting CFO — — Peter Soparkar appointed COO — —…